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Abstract
Background:  High antibiotic resistance is described in atypical Mycobacteriosis, mainly by
Mycobacterium avium complex (MAC).
Methods: A randomized, double-blind, placebo-controlled clinical trial was carried out in two
hospitals to evaluate the effect of interferon (IFN) gamma as immunoadjuvant to chemotherapy on
patients with atypical mycobacteria lung disease. Patients received placebo or 1 × 106  IU
recombinant human IFN gamma intramuscularly, daily for one month and then three times per
week up to 6 months as adjuvant to daily oral azithromycin, ciprofloxacin, ethambutol and rifampin.
Sputum samples collection for direct smear observation and culture as well as clinical and thorax
radiography assessments were done during treatment and one year after. Cytokines and oxidative
stress determinations were carried out in peripheral blood before and after treatment.
Results: Eighteen patients were included in the IFN group and 14 received placebo. Groups were
homogeneous at entry; average age was 60 years, 75% men, 84% white; MAC infection prevailed
(94%). At the end of treatment, 72% of patients treated with IFN gamma were evaluated as
complete responders, but only 36% in the placebo group. The difference was maintained during
follow-up. A more rapid complete response was obtained in the IFN group (5 months before), with
a significantly earlier improvement in respiratory symptoms and pulmonary lesions reduction.
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Disease-related deaths were 35.7% of the patients in the placebo group and only 11.1% in the IFN
group. Three patients in the IFN group normalized their globular sedimentation rate values.
Although differences in bacteriology were not significant during the treatment period, some
patients in the placebo group converted again to positive during follow-up. Significant increments
in serum TGF-beta and advanced oxidation protein products were observed in the placebo group
but not among IFN receiving patients. Treatments were well tolerated. Flu-like symptoms
predominated in the IFN gamma group. No severe events were recorded.
Conclusion: These data suggest that IFN gamma is useful and well tolerated as adjuvant therapy
in patients with pulmonary atypical Mycobacteriosis, predominantly MAC. Further wider clinical
trials are encouraged.
Trial registration: Current Controlled Trials ISRCTN70900209.
Background
The prevalence of isolated atypical Mycobacteria (also
called non-tuberculous Mycobacteria) infection is grow-
ing and is suspected to surpass Mycobacterium tuberculosis
in some areas. Mycobacterium avium complex (MAC) spe-
cies are the most frequent. Immunocompetent patients
develop lung disease as a progressive chronic pneumonia.
In the United States and in Japan there are approximately
1.3 cases per 100 000 persons, whereas in Switzerland,
there are 0.9 cases per 100 000 persons with pulmonary
MAC. It is postulated that up to 70% of patients with pul-
monary MAC infection had a previous bronchopulmo-
nary disorder [1]. However, cases without a predisposed
previous condition or identifiable immunodeficiency also
exist [2].
Atypical Mycobacteria can survive and proliferate within
the hostile environment of host macrophages [3,4]. The
treatment of these pulmonary infections is more difficult
than Mycobacterium tuberculosis due to a higher drug resist-
ance. MAC and Mycobacterium fortuitum-cheloneae are the
two most resistant. The problem to choose an adequate
antibiotic combination derives from the lack of control-
led, prospective studies. The different populations, bacte-
riological methods and cure approaches applied, as well
as lack of correlation between clinical and laboratory
results add higher complexity. Conventional chemother-
apy is prolonged and associated to frequent toxicities [5-
7]. Mortality attributed directly to infection occurs, but its
rate is ignored.
Therefore, an alternative therapeutic target can be directed
to the manipulation of the host's defenses. As most of the
intracellular infections, the immune response to control
infection depends primarily on a Th1 lymphocytes out-
break [8]. Interferon (IFN) gamma, a glycoprotein pro-
duced primary by CD4+ cells, plays a main role in this
process. Enough evidences exist related to the action of
IFN gamma on the immunoregulatory activity of macro-
phages [9]. Lack of production of this cytokine [10] or
expression of its receptor [11-13] is associated to the infec-
tion's most lethal forms. IFN gamma has also a potent
antifibrotic effect [14,15].
Previous clinical studies have demonstrated satisfactory
results with the use of recombinant IFN gamma in
patients infected with atypical Mycobacteria [16-20].
However, none of these reports was a controlled trial and
they included only few patients. The present placebo-con-
trolled study was done with the objective to assess the
immunoadjuvant IFN gamma effect in patients with pul-
monary atypical Mycobacteriosis regarding their clinical,
bacteriological and radiological evolutions. Additionally,
several immune response and oxidative stress markers
were measured. The safety of the procedure was also eval-
uated.
Methods
A randomized, double-blind, placebo-controlled trial was
carried out at the "Benéfico Jurídico" Hospital, Havana,
which is the national reference unit for tuberculosis and
other respiratory diseases and where most of the patients
with unfavorable evolution are remitted. Another partici-
pant institution was the "Amalia Simoni" Hospital,
Camagüey. The clinical protocol was approved by the Eth-
ics Committees of the corresponding sites and by the
Cuban Regulatory Authority. The study complied with the
Declaration of Helsinki.
Patients
The study population was constituted by Cuban patients,
more than 18 years-old with diagnosis of pulmonary atyp-
ical Mycobacteriosis, who gave their written, informed
consent to participate. The diagnosis comprised isolation
and classification of any of the atypical Mycobacteria spe-
cies three or more times in sputum-culture samples,
symptoms such as cough and expectoration, and tubercu-
losis-like pulmonary lesions at thorax radiography. Exclu-
sion criteria were other concomitant pulmonary
infections, chronic diseases or neoplasia, pregnancy orBMC Infectious Diseases 2008, 8:17 http://www.biomedcentral.com/1471-2334/8/17
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nursing, severe psychiatric dysfunction, multiple sclerosis
or any other autoimmune disorder, HIV co-infection,
hypersensitivity to IFN gamma or any other drug used in
the trial, and treatment with corticosteroids or other
immunosuppressor medication. Patients that had
received any type of IFN during the 3 previous months
were also excluded.
Study design and treatment
Patients were distributed according to a computer-gener-
ated random number list, stratified by center, to receive
intramuscular IFN gamma as adjuvant to oral chemother-
apy (IFN group) or chemotherapy plus placebo (placebo
group) during 6 months. The study was double-blinded.
IFN gamma and placebo vials looked the same, labeled
with the hospital code and the patient's inclusion
number. Their composition differed only regarding the
presence of IFN. Random lists were kept at the sponsor's
product-preparation department, where vials were
labeled. This group was independent from the monitors,
investigators or other trial participants. All clinical and
laboratory evaluations were done blindly regarding the
patients' group allocation. The code was opened only in
case of serious adverse events, deaths or at the end of the
study, after databases closure.
Treatment schedule consisted in 1 × 106 IU of human
recombinant IFN gamma (produced in E. coli, specific
activity: 1 × 107 IU/mg of proteins; Heberon Gamma R®,
Heber Biotec, Havana) or placebo intramuscularly, daily
during 4 weeks and then 3 times per week for the next 20
weeks. All the patients received the same conventional
antibiotic schedule. Drugs were given orally, daily as fol-
lows: azithromycin 500 mg, ciprofloxacin 1000 mg,
rifampin 600 mg, and ethambutol 2000 mg.
Subjects were hospitalized during the first 4 weeks of
treatment to check the initial evolution and for a better
assessment of immediate adverse events. Antipyretic med-
ication was given orally at the same time as the first IFN
injections, in order to mitigate the expected IFN-depend-
ent flu-like syndrome and keep the blinding. Afterwards,
patients were followed up to 18 months as out-patients.
Non-responders or relapsers continued under antibiotic
therapy during this period.
Evaluation
The main efficacy outcome was an overall response that
integrated clinical, bacteriological and radiological
results, at the end of treatment (month 6) and after 12
additional months of follow-up (month 18). This com-
posite variable was considered as complete if all symp-
toms disappeared, sputum acid-fast-bacilli smear and
culture were negative, and X-ray pulmonary lesions
improved. Partial response included symptoms decrease,
negative sputum smear and culture, and improvement or
stabilization at X-ray. Symptoms persistence, positive bac-
teriological examinations, or X-ray lesion progression was
considered as no response. The clinical, radiological and
bacteriological evaluations were also taken independently
as secondary variables, as well as time to response and
overall survival.
The reduction or disappearance of the respiratory symp-
toms was the first criteria to consider clinical improve-
ment. Physical examination of the respiratory tract,
bodyweight, vital signs and any other particular character-
istic were taken into account. General clinical status was
classified as good, moderate or bad. Good: none or dis-
creet respiratory symptoms without frequent or serious
exacerbations, appropriate bodyweight; moderate: main-
tained respiratory symptoms with more acute exacerba-
tions, appropriate bodyweight; bad: maintained serious
respiratory symptoms (intense dyspnea, cough, and abun-
dant expectoration), low bodyweight. General clinical sta-
tus improvement was considered when the patient passed
from "bad" to "moderate" or from "moderate" to "good".
Sputum samples were taken for acid-fast-bacilli smear and
culture. Regular specimen staining methods (Zielh-
Neelsen) and culture (Lowenstein-Jensen medium) were
used. Atypical Mycobacteria  species were identified by
characteristic colony morphology, growth rate, and pig-
mentation (the Runyon classification system), using a bat-
tery of routine chemical reactions. Codification was
defined as the number of bacilli counted in 300 fields on
the direct observation or the number of colonies grown in
the culture as follows: code 0: no bacilli or colonies; code
1 to 5: the same number of bacilli counted or colonies
grown; code 6: 6 – 24 bacilli or colonies; code 7: 25 – 100
bacilli or colonies; code 8: more than 100 bacilli or colo-
nies; code 9: bacilli in most fields counted or continuous
growth.
Pulmonary lesions extension at radiography was consid-
ered minimum if they comprised up to one third of a lung
area; moderate up to one lung involvement, and advanced
if more extensive. Radiological worsening was defined by
the presence of new infiltrates, cavitations, multiple nod-
ules or increase of the fibrosis area. Stabilization was con-
sidered when new lesions did not appear and the
extension of fibrosis-derived damage did not increase.
Lesion extension reduction together with respiratory
symptoms decrease was taken as improvement.
Safety and tolerability were monitored by means of a rig-
orous adverse events control. Additionally, blood samples
were taken for routine hematological and biochemical
determinations.BMC Infectious Diseases 2008, 8:17 http://www.biomedcentral.com/1471-2334/8/17
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Laboratory procedures
Gene modulation was studied in both groups before and
after the 6 months treatment using a RT-PCR for mRNA
expression. Briefly, peripheral blood mononuclear cells
(PBMC) were separated from heparinized whole blood
(10–15 mL) by Ficoll-Paque plus (Amersham Bioscien-
cies, endotoxin tested) gradient centrifugation and RNA
was extracted using the acid guanidium thiocyanate-phe-
nol-chloroform method. RNA was then reverse tran-
scribed using the Perkin Elmer core kit (Perkin-Elmer/
CETUR, Norwalk, CT). Samples were incubated 10 min at
room temperature and then 15 min at 42°C and 5 min at
99°C. Primers used were: 5'-CCA TGG AGA AGG CTG
GGG-3' and 5'-CAA AGT TGT CAT GGA TGA CC-3' for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
5'-ATG AAA TAT ACA AGT TAT ATC TTG GCT TT-3' and
5'-GAT GCT CTT CGA CCT CGA AAC AGC AT-3' for IFN
gamma, 5'-TGC CAG GCA GGT TCT CTT CC CG-3' and
5'-GGT TAT CTC TCA GCT CCA CGC CA-3' for tumor
necrosis factor (TNF) alpha, 5'-CAA GCA GAG TAC ACA
CAG CA-3' and 5'-GAT GCT GGG CCC TCT CAA GC-3'
for transforming growth factor (TGF) beta, 5'-AAC TGA
AGC TCG CAC TCT CG-3' and 5'-TCA GCA CAG ATC TCC
TTG GC-3' for monocyte chemoattractant protein (MCP)-
1, 5'-AAG GTG GCA GGA TGT CTC GTG-3' and 5'-TGG
TCT CGT GTT CTT CTG TTC TG-3' for signal transducer
and activator of transcription (STAT)-1, 5'-AAC AAG ACC
CAG ACA TCA AG-3' and 5'-GAG GTA CAA TAA GGT TTC
TCA AG-3' for interleukin (IL)-10 and 5'-GAT GTT TGT
GGA CGT GGT CTT G-3' and 5'-GAT GTT TGT GGA CGT
GGT CTT G-3' for transcription factor associated to Th1
lymphocytes (T-bet). Amplification was done in an auto-
matic thermal cycler (Eppendorff) at 94°C for 30 sec,
56°C for 30 sec. and 72°C for 30 sec. After 35 cycles, PCR
amplification products were resolved following separa-
tion by 2% agarose gel electrophoresis. The bands were
visualized by ethydiumbromide staining and then quanti-
fied by gel densitometric scanning (Molecular Analyser
software for Windows, version 1.4.1). The ratios between
target cDNA and GAPDH as housekeeping gene were eval-
uated and expressed as relative amount of genetic expres-
sion.
Oxidative stress parameters were also measured in serum
before and after treatment using an ultramicroanalitic sys-
tem and the Ultrospect Bonus Spectrophotomer (Pharma-
cia LKB). Total superoxide dismutase (SOD) activity was
determined using the pyrogallol autoxidation method.
Catalase activity was evaluated following hydrogen perox-
ide decomposition [21]. Lipid peroxidation was measured
through malonyldialdehyde (MDA) concentration [22].
Potential lipid peroxidation products (PLPP) [23], total
hydroperoxides (THP) [24] and advanced oxidation pro-
tein products (AOPP) [25] were also measured, as recom-
mended.
Hematological counts and blood chemistry were done
according to usual clinical laboratory procedures, using
advanced automated analyzers. These included hemo-
globin, hematocrit, globular sedimentation rate (GSR),
leukocytes and platelets counts, transaminases, bilirubin,
creatinine and urea. All laboratory analyses were done
blindly.
Statistics
Sample size was calculated using the log-rank test ("2N
Program for Design of Clinical Trials") assuming a 30%
overall response in the control group and 90% in the IFN
group, with 0.05 and 0.8 for types I and II errors, respec-
tively, at six months of evaluation. A 20% excess was con-
sidered to compensate withdrawals. This yielded a total of
34 patients for the trial.
Data were double entered and validated on Microsoft
Access and then imported into SPSS version 13.0 for fur-
ther analysis. Continuous variables were expressed as
mean ± standard deviation (SD) or median ± interquartile
range (QR) and minimum and maximum values (range).
With these variables a normality analysis (Shapiro Wilk's
test) and homogeneity of variance (Levene's test) were
carried out. Categorical variables were given as frequen-
cies and percentages. Times to response and survival were
expressed as mean ± standard error (SE) and their 95%
confidence interval. Groups were compared using the
Fisher's exact or chi-square tests for all categorical varia-
bles and the Student's t-test (parametrical) or Mann-Whit-
ney's U test (non-parametrical) for continuous variables.
The log-rank test was used to compare times to response
and survival. Kaplan-Meier survival curves were also esti-
mated. Significance level chosen was 0.05. Analyses of the
overall response and clinical outcome were done under
"intention-to-treat" basis, where missing data were con-
sidered as failures. Stratified analyses according to investi-
gation site were not possible due to the small sample size
in one of them (see below).
Results
Thirty-two patients were enrolled from October 2002 to
March 2005; then follow-up continued up to September
2005. Eighteen patients received IFN gamma and 14 pla-
cebo. Most of the patients (84.4%) corresponded to
"Benéfico Jurídico" Hospital. Table 1 summarizes the
course of the trial. Sixteen patients (88.9%) completed the
6-months treatment period in the IFN group (two aban-
doned after the first month), while 10 (71.4%) completed
it in the placebo group. Withdrawals in this latter group
were 2 deaths after the first month (MAC infection and
pulmonary thromboembolism) and 2 voluntary aban-
dons after months 2 and 5. The patient that abandoned
after the second month of treatment died 2 months later
due to a lung cancer, not present at entry or at withdrawal.BMC Infectious Diseases 2008, 8:17 http://www.biomedcentral.com/1471-2334/8/17
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During follow-up 2 patients died in the placebo group
(myocardial infarction and pulmonary thromboembo-
lism) and other 2 in the IFN group (both myocardial inf-
arctions). In addition, one IFN patient did not attend the
last evaluation. Finally, 13 patients (72.2%) completed
the entire study in the IFN group, and 8 (57.1%) in the
placebo group.
Baseline characteristics of the included patients are shown
in Tables 2 and 3. Groups were homogeneous. Even if
there were noteworthy differences concerning smoking
and alcohol drinking habits, the sample size does not pro-
vide enough power to assess their relation to response.
Mean age was around 60 years for both groups and white
men prevailed (> 70%). M. avium-intracellulare complex
was 94% of the isolated species. None of the respiratory
antecedents stood out particularly. All the patients pre-
sented breathing disorders (movements, crepitations) at
physical examination, but none had any extra-pulmonary
manifestation of the disease.
The results of the evaluations are shown in Table 3. The
overall response, which was the main study outcome, was
significantly better in those patients treated with the com-
bination (72% vs. 36%). All responses were complete,
except for one patient in the IFN group who responded
partially after treatment but reached complete response at
the end of follow-up. The difference persisted during the
follow-up (67% vs.29%). These analyses were done under
the intention-to-treat principle, where all withdrawals are
considered as failures. If the analysis is made with each
patient's last evaluation differences are larger and more
significant.
The clinical, radiological, and bacteriological assessments
taken independently were also better for the IFN gamma
group. Improvement was obtained for the presence of res-
piratory symptoms such as dyspnea only in the IFN group.
Additionally, withdrawals in this group were also asymp-
Table 1: Course of the trial.
IFN gamma Placebo
Randomized patients 18 14
Treatment interruptions 2 (11.1%) 4 (28.6%)
Voluntary abandoners 2 (11.1%) 2 (14.3%)
Deaths 0 2 (14.3%)
Completed 6 months of treatment 16 (88.9%) 10 (71.4%)
Follow-up withdrawals 3 (16.7%) 2 (14.3%)
Voluntary abandoners 1 (5.5%) 0
Deaths 2 (11.1%) 2 (14.3%)
Completed 12 months of follow-up 13 (72.2%) 8 (57.1%)
Total deaths 2 (11.1%) 5* (35.7%)
* One of the voluntary abandoners in this group died
Table 2: Characteristics of the study population at entry.
Characteristic IFN gamma N = 18 Placebo N = 14
Age (yrs), median ± IQR 62 ± 11 57 ± 18
Male gender 13 (72.2%) 11 (78.6%)
White 16 (88.9%) 11 (78.6%)
BMI (Kg/m2), mean ± SD 21.1 ± 3.5 18.7 ± 2.8
Toxic habits
Smokers 5 (27.8%) 7 (50.0%)
Alcohol 1 (5.6%) 5 (35.7%)
Organism
M. avium complex 17 (94.4%) 13 (92.9%)
M. fortuitum-cheloneae 1 (5.6%) 0
M. kansasii 01  ( 7 . 1 % )
Months since diagnosis, median ± IQR 30 ± 40 40 ± 34
Respiratory tract history
Asthma 0 2 (14.3%)
Tuberculosis 2 (11.1%) 0
Minimum pleurotomy 2 (11.1%) 0
Right superior lobectomy 0 1 (7.1%)
Emphysematous bullous disease 1 (5.6%) 0
Fibroemphysema 0 1 (7.1%)
Interstitial pulmonary fibrosis 1 (5.6%) 0
Pneumothorax 1 (5.6%) 0
BMI: Body mass index.BMC Infectious Diseases 2008, 8:17 http://www.biomedcentral.com/1471-2334/8/17
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Table 3: Clinical, radiological, bacteriological and overall outcomes during the trial.
Evaluation Month IFN gamma Placebo P (test)
Overall response
Responders (a) (intention-to- treat) 6 13/18 (72.2%) 5/14 (35.7%) 0.037 (χ2)
18 12/18 (66.7%) 4/14 (28.6%) 0.030 (χ2)
Responders (last evaluation) 15/18 (83.3%) 5/14 (35.7%) 0.005 (χ2)
Clinical
Dyspnea 0 15/18 (83.3%) 13/14 (92.9%)
6 1/15 (6.7%) 3/9 (33.3%) 0.27 (FE)
18 1/13 (7.7%) 3/8 (37.5%) 0.25 (FE)
BMI (kg/m2), mean ± SD 0 21.1 ± 3.5 (N = 18) 18.7 ± 2.8 (N = 14)
6 21.8 ± 3.7 (N = 14) 19.4 ± 3.0 (N = 9) 0.88 (St)
18 22.9 ± 4.4 (N = 13) 19.9 ± 3.9 (N = 8) 0.15 (St)
Good general status (intention-to-treat) 0 3/18 (16.7%) 4/14 (28.6%)
6 13/18 (72.2%) 5/14 (35.7%) 0.037 (χ2)
18 12/18 (66.7%) 4/14 (28.6%) 0.03 (χ2)
Improvement (b) (intention-to-treat) 6 13/18 (72.2%) 5/14 (35.7%) 0.037 (χ2)
18 12/18 (66.7%) 4/14 (28.6%) 0.03 (χ2)
Radiological
Lesion extension 0 Adv 12 (66.7%) 11(78.6%)
Mod 5 (27.8%) 3 (21.4%)
Min 1 (5.6%) 0
6 Adv 2 (13.3%) 5 (55.6%) 1.00c (FE)
Mod 12 (80.0%) 3 (33.3%)
Min 1 (6.7%) 1 (11.1%)
18 Adv 1 (7.7%) 2 (25.0%) 0.085c (FE)
Mod 5 (38.5%) 5 (62.5%)
Min 7 (53.8%)d 1 (12.5%)
Improvement (intention to treat) 6 12/18 (66.7%) 6/14 (42.8%) 0.32 (χ2)
18 13/18 (72.2%) 4/14 (28.6%) 0.036 (χ2)
Cavitary lesions disappearance 5/12 (41.7%) 1/12 (8.3%) 0.15 (FE)
Bacteriological
Sputum- Direct (+) 0 14/18 (77.8%) 10/14 (71.4%)
Cod. 7 ± 4 8 ± 8
6 1/15 (6.7%) 2/10 (20.0%) 0.54 (FE)
Cod. 0 ± 0 0 ± 2 0.28 (MW)
18 1/13 (7.7%) 3/8 (37.5%) 0.253 (FE)
Cod. 0 ± 0 0 ± 7 0.112 (MW)
Relapse 1/13 (7.7%) 3/8 (37.5%) 0.25 (FE)
Sputum- Culture (+) 0 18 (100%) 14 (100%)BMC Infectious Diseases 2008, 8:17 http://www.biomedcentral.com/1471-2334/8/17
Page 7 of 13
(page number not for citation purposes)
tomatic, which only happened for one of the placebos.
BMI increments were also larger among IFN treated
patients. Regarding clinical general status and its improve-
ment, statically significant differences were achieved.
Importantly, 7/14 patients from the IFN group but none
among the controls improved their general status (passed
from "bad" to "moderate" or from "moderate" to "good")
just one month after the therapy onset. Among survivors,
there were two patients in the placebo group who wors-
ened their general clinical condition. The only patient
where this happened in the IFN group was infected with
M. fortuitum-cheloneae.
All patients, except one in the IFN group, presented
fibrotic lesions. Twelve individuals in each group had cav-
itations. Pleural thickness and interstitial and/or alveolar
infiltrate were seen in 15 and 13 subjects, respectively.
Apical and parahilar lesion localization were most com-
mon. Advanced lesions predominated at entry in both
groups. At the end of treatment more patients treated with
IFN gamma reduced lesion extension: advanced lesions
persisted in only 3 patients from this group vs. more than
half in the placebo group. A 61 years-old male, 2 years
with the disease, which initially had advanced lesions evi-
denced a total disappearance of lesions after IFN treat-
ment and follow-up (Figure 1). The other 12 patients in
Cod. 8 ± 2 9 ± 4
6 2/15 (13.3%) 2/10 (20.0%) 1.00 (FE)
Cod. 0 ± 0 0 ± 2 0.60 (MW)
18 1/13 (7.7%) 4/8 (50.0%) 0.11 (FE)
Cod. 0 ± 0 0 ± 8 0.042 (MW)
Relapse 1/13 (7.7%) 3/8 (37.5%) 0.25 (FE)
(St): Student's t test; (MW): Mann-Whitney's U test; all binary variable comparisons were with the Fisher's exact test.
(a) All overall responses were complete except for one IFN group case at month 6 with partial response.
(b) General clinical status improvement if the patient passed from "bad" to "moderate" or from "moderate" to "good".
Adv: Advanced; Mod: Moderate; Min: Minimum; (c) Combining advanced-moderate;
dOne of them had lesions disappearance at this time.
Table 3: Clinical, radiological, bacteriological and overall outcomes during the trial. (Continued)
Radiological improvement with IFN gamma treatment as adjuvant to chemotherapy Figure 1
Radiological improvement with IFN gamma treatment as adjuvant to chemotherapy. (A): Advanced fibrosis and cavitations, 
sited on vertex and parahilar areas, and (B) complete resolution of the lesions after treatment and follow-up.
A BBMC Infectious Diseases 2008, 8:17 http://www.biomedcentral.com/1471-2334/8/17
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the IFN group who where evaluated at month 18
improved their radiological condition, 5 of them reached
the minimum lesion extension and 4 up to moderate. On
the contrary, among the controls, 6 improved, but only
one reached minimum extension, and it was a subject
bearing M. kansasii infection. Additionally, one patient in
this group worsened his status at 18 months follow-up.
Cavitary lesions disappeared in 5 patients in the IFN
group (42%), at an average of 6 months (range: 1 – 12
months), but only in the M. kansassi bearing patient in the
placebo group (8%), at 5 months.
Bacteriological response by direct examination and cul-
ture occurred in both groups at the end of treatment.
However, during follow-up there were more relapses in
the placebo group (3 vs. 1 in the experimental group) and
besides, there was one late positive sputum conversion to
negative among the IFN receiving patients. Statistically
significant differences were attained regarding sputum
culture codification at the end of follow-up.
Overall complete response was obtained earlier in
patients treated with the combination (Figure 2; log rank
test, p = 0.024). Interestingly, the only complete
responder at 1st month of treatment corresponded to the
IFN group. All symptoms disappearance, or particularly
dyspnea, and radiological improvement behaved the
same (graphs not shown). The most important differences
in improvement rate concerned the radiological evalua-
tion. After one month of treatment, 4 patients in the IFN
group but none among placebos showed pulmonary
lesions improvement. At this point, 60% of patients with
initial dyspnea in the IFN group, no longer presented this
symptom, in contrast to16.7% in the other group.
Survival profiles are shown in Figure 3. During the entire
study, 5 patients (35.7%) deceased in the control group
(median survival: 4.5 months) and only 2 (11.1%) in the
IFN group. Both deaths in the IFN group occurred at 16
months, as complete responders. Among the control
patients, 4 died as non-responders and the other one as
partial responder.
Oxidative stress parameters basal mean values were
importantly increased in the patients as compared to a
group of 60 Cuban healthy individuals [26] (Table 4). Sig-
nificant decrements in SOD and AOPP values were
detected in the IFN group (Table 5). The difference was
more pronounced for AOPP, since it decreased in 9/10
IFN treated patients whereas increased in 5/7 from the
placebo group. For the other parameters important
changes were not perceived.
Regarding gene modulation, the most important varia-
tions were detected within the groups after treatment
(Table 5). TGF beta increased significantly in the placebo
group, whereas MCP-1 decreased in the IFN gamma
group. TNF alpha values, although slightly different
before treatment, increased significantly in the placebo
group, while did not change with IFN therapy. No
changes were detected for the other genes evaluated
(results not shown).
Seventeen adverse events were presented during the treat-
ment (Table 6). At least one event occurred in 66.7% of
the patients in the IFN group and 42.9% in the placebo
Kaplan-Meier estimates of probability of overall complete  response in patients with pulmonary atypical Mycobacteriosis  treated with IFN gamma (solid line) or placebo (dashed line)  adjuvant to chemotherapy Figure 2
Kaplan-Meier estimates of probability of overall complete 
response in patients with pulmonary atypical Mycobacteriosis 
treated with IFN gamma (solid line) or placebo (dashed line) 
adjuvant to chemotherapy.
Time (months)
Kaplan-Meier estimates of probability of overall survival  among patients with pulmonary atypical Mycobacteriosis  treated with IFN gamma (solid line) or placebo (dashed line)  adjuvant to chemotherapy Figure 3
Kaplan-Meier estimates of probability of overall survival 
among patients with pulmonary atypical Mycobacteriosis 
treated with IFN gamma (solid line) or placebo (dashed line) 
adjuvant to chemotherapy.
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group. Arthralgias (50.0%), fever (44.4%), chills (33.3%),
anorexia (27.8%) and asthenia (22.2%) prevailed in the
IFN group, where a higher frequency was detected for
fever and chills, which were not present in the placebo
group. Most of the events in the IFN group were classified
as moderate (60%), none of them severe. All of them were
well controlled with or without treatment. Respiratory or
cardiorespiratory manifestations, closely related to the
disease, were not accounted as adverse reactions.
Significant differences or variations in vital signs and clin-
ical laboratory tests were not detected. Only a moderate
creatinine increase and a mild anemia in a single patient
of the IFN group were considered as adverse reactions. On
the contrary, in this group, 3 patients with complete
response normalized their GSR values, 2 of them with ini-
tial values > 100 mm/h. A mean reduction of 22 mm/h
(71 to 49 mm/h) took place in the IFN group, while in the
placebo group GSR values remained stable.
Discussion
This report constitutes the first and largest randomized,
controlled clinical study, using an immunomodulating
agent systemically in atypical Mycobacteria infection. The
group of patients treated with IFN gamma and antibiotics
had a better response from the clinical, radiological and
bacteriological points of view. Response rate in the IFN
group doubled that from the controls after 6 months of
treatment and the difference persisted after one year fol-
low-up. Patients that received IFN gamma responded 5 to
6 months before those with placebo, with respect to all
evaluation criteria. The earlier disappearance of dyspnea
in the IFN group was remarkable since this symptom
affects quality of life more than others. This was not only
statistically but also clinically significant. There was also
an advantage in overall survival. In fact, except for one
case, all patients treated with IFN gamma received benefit
from treatment. The 66.7% response rate was calculated
under intention-to-treat basis, considering the abandon-
ers and deceased as failures. But in this group one of the
abandoners had complete response at withdrawal after
the first month of treatment and the two deaths were due
to myocardial infarcts. Both deceased cases had had com-
plete response at the end of treatment. In the control
group one of the abandoners had responded but four of
the five deceased were non responders.
Advanced age and male gender predominated in this
study, comparable to reported [1]. However, antecedents
of respiratory tract affectations were scarce. As expected,
MAC species predominated. M. fortuitum-cheloneae was
present in one patient of the IFN group, which was the
only one that did not receive benefits from treatment.
Coincidently, infection by this species has been reported
in patients with anti-IFN gamma autoantibodies [27].
Nevertheless, infection with this specie is less common.
The other species, M. kansassi, presented in one patient
with placebo, is more sensitive to first line therapy. This
patient was the best responder in this group; the only one
where cavitary lesions disappeared. Obviously, differ-
ences between groups could be more significant if no-
Table 6: Adverse events during treatment.
Adverse reaction IFN gamma N = 18 Placebo N = 14
Any adverse event 12 (66.7%) 6 (42.9%)
Arthralgias 9 (50%) 2 (14.3%)
Fever 8 (44.4%) 0
Chills 6 (33.3%) 0
Anorexia 5 (27.8%) 2 (14.3%)
Asthenia 4 (22.2%) 0
Headache 3 (16.7%) 0
Diarrhea 2 (11.1%) 1 (7.1%)
Pruritus 2 (11,1%) 1 (7.1%)
Epigastralgia 1 (5.6%) 1 (7.1%)
Myalgias 0 1 (7.1%)
Vomiting 1 (5.6%) 0
Depression 0 1 (7.1%)
Anemia 1 (5.6%) 0
Pain at the injection site 1 (5.6%) 0
Increase of creatinine 1 (5.6%) 0
Limb edema 0 1 (7.1%)
Nausea 0 1 (7.1%)
Table 4: Comparison of oxidative stress parameters between patients with pulmonary atypical Mycobacteriosis and healthy 
individuals.
Parameter Patients N = 18 Healthy subjects N = 60 (from ref. 27)
Catalase (U/mL/min) 457 ± 286 162 ± 23
SOD (U/mL/min) 32.4 ± 15.7 1.5 ± 0.1
Catalase/SOD 0.02 ± 0.02 0.11± 0.20
AOPP (µM) 70.1 ± 30.2 12.1 ± 0.9
MDA (µM) 16.8 ± 9.8 1.8 ± 0.1
PLPP (µM) 37.1 ± 20.0 7.6 ± 1.3
THP (µM) 181.7 ± 69.6 103.8 ± 17.7
Data are expressed as mean ± SD.BMC Infectious Diseases 2008, 8:17 http://www.biomedcentral.com/1471-2334/8/17
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MAC species are excluded from analysis, but this was not
previewed in the protocol.
The antibiotic scheme used in this trial was in correspond-
ence with the best update recommended. Based on in vivo
and in vitro studies treatment should include: (i) a mac-
rolide (clarithromycin or azithromycin), (ii) ethambutol,
(iii) rifampin or rifabutin, and (iv) ciprofloxacin, strepto-
mycin or clofazimine. However, the response level
obtained in the IFN group is rarely achieved with antibi-
otics only. Besides, clinical studies are not controlled,
often use more flexible response criteria and longer peri-
ods of treatment [28].
Radiological response during treatment was the most sig-
nificant benefit added by IFN gamma. Improvement was
evident since the first month and there was even complete
lesion disappearance in one patient, which has not been
reported after such a relatively short follow-up time. This
lesion extension reduction had consequences on the
patients' clinical performance with dyspnea and other
symptoms reduction or disappearance. In this case, radi-
ology had a higher clinical impact than bacteriology. Sev-
eral patients in the placebo group even with sputum
conversion, never experienced radiological improvement,
most of them worsened lesions and had bacteriological
relapse. Contrarily, in the IFN group, some patients with
sputum-culture positive had an early lesions reduction,
with symptoms disappearance and had later complete
response. Improvement difference included not only cav-
itary lesions reduction (42% vs. 8%) but also fibrosis and
infiltrate extension. This suggests a different mechanism
for the additional radiological improvement, probably
related to the potent antifibrotic effect of IFN gamma,
whether the Mycobacterium is present or not.
Treatment was well tolerated. Flu-like symptoms such as
fever, chills and arthralgias are among those expected for
interferons since their first clinical applications [29].
Reduction in blood cell counts and moderate creatinine
increase, which appeared in one case each have been also
reported. Gastrointestinal events (vomiting, diarrheas)
are probably more related to the use of the antibiotics
[1,5,7]. All deaths in the IFN group were during the fol-
low-up period so they are unlikely related to treatment.
However deaths can be related direct or indirectly to the
disease since it is a predisposing factor for lung cancer,
pulmonary thromboembolism, and myocardial infarc-
tion, which are all preceded by cardiorespiratory events.
The role of IFN gamma as the main macrophage – activa-
tor Th1 cytokine has been clearly established in animal
models infected with M. avium [30,31]. IFN gamma
action on the macrophages leads to intracellular Mycobac-
teria killing. It stimulates macrophages to produce TNF
alpha, oxygen free radicals and nitric oxide, increases
MHC surface antigens and Fc receptors display, decreases
lysosomal pH, and increases the intracellular concentra-
tion of some antibiotics (e.g. macrolides) [9,30]. There-
fore, its use as adjuvant is justified since existent
multidrug therapy, despite its limited efficacy, must be
offered to the patients.
Regarding its antifibrotic effect, IFN gamma inhibits lung
fibroblast proliferation and chemotaxis in a dose depend-
ent manner and reduces collagen synthesis [14]. Further-
more, this protein is a potent antagonist of TGF beta [15],
involved directly in severe lung fibrosis progression [32].
IFN gamma contributes to the tissue repair and its remod-
eling [33]. These actions were also evident in the results
reported with IFN gamma in patients with idiopathic pul-
monary fibrosis [34,35] and suggests that this cytokine
could have future indications in other pulmonary diseases
where fibrosis is present, although a definite effect on sur-
vival is still to be demonstrated.
Systemic or aerosolized IFN gamma have been reported as
satisfactory in other similar intracellular infections [36-
41], but none of these studies was controlled. The concept
that IFN gamma can be useful in these atypical Mycobac-
terial infections is supported by several reports on individ-
uals where the IFN gamma action is impaired. Mutations
in the IFN gamma receptor genes are associated with fre-
quent recurrences or the most serious forms of the disease
[11-13]. Patients with defects in the production of IFN
gamma or other cytokines or partial deficiencies of IFN
gamma receptor can obtain benefits with IFN gamma
treatment [10,13,42]. Additionally, patients without
genetic disorders but with serum anti-IFN gamma autoan-
tibodies have a higher susceptibility to develop Mycobac-
teriosis [43].
IFN gamma has been effective as adjuvant in AIDS
patients co-infected with MAC, where a clear decrement in
the bacteremia was verified. These results were obtained
in patients with low CD4+ lymphocytes counts, suggest-
ing a non T cell-mediated effect [16]. Fifteen patients with
disseminated MAC and other nontuberculous mycobacte-
ria infections were treated subcutaneously during one year
or more, 13 of them improved and 7 had even apparent
disease eradication [20]. Other groups of HIV negative
immunocompromised patients infected with M. avium
received clinical and bacteriological benefits of this treat-
ment as well [17,18]. Short courses of the cytokine admin-
istered by alveolar route seemed to be effective in
pulmonary MAC, since their use in one patient [19]. How-
ever, it has been recently reported that a randomized trial
testing this option was stopped early due to lack of effi-
cacy [44]. Since different routes of administration (aero-BMC Infectious Diseases 2008, 8:17 http://www.biomedcentral.com/1471-2334/8/17
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sols, subcutaneous, intramuscular) have been used, this
aspect should be further investigated.
Oxidative stress indicates an excessive production of oxy-
gen reactive species (ROS), together with an inadequate
antioxidant defense [45]. Scarce information exists about
pulmonary infections including M. avium in this sense.
The redox unbalance was evidenced through oxidative
damage markers increments, as shown by the comparison
with healthy control reference values. AOPP are consid-
ered as the major free radicals-dependant protein damage
indicator [46]. As result of the exposition to radicals, pro-
teins could suffer modifications, fragmentation, aggrega-
tion, changes on the absorption, decrease or loss of their
biological function or proteolysis [47]. After treatment, a
significant reduction was detected in the IFN group. Their
decrease or return to normal values can be secondary to
infection eradication. In the same group, a SOD reduction
was also observed. Although SOD plays a role in the
defense against toxic oxygen metabolites, in most of the
cases its presence indicates tissue damage and participates
in reactions that drive to formation of hydrogen peroxide
and iron, producers in turn of new toxic molecules [48].
Therefore, their decrease can be taken as another favorable
presage.
Genetic modulation data obtained are consistent with the
clinical results. A significant increment in TGF beta was
obtained in the placebo group. This factor counteracts T-
cell proliferation and the production of IFN gamma, TNF
alpha and pro-inflammatory chemokines [49], in addi-
tion to its pro-fibrotic activity [33], and thus helps Myco-
bacteria to avoid immune reactions and survive. MCP-1
participates in leukocyte recruitment toward granuloma
[50]. It also inhibits IL-12 production favoring infection
[51]. Therefore, MCP-1 decrease in the IFN group could be
associated to pathogen control leading to granuloma res-
olution. The same interpretation is possible for the TNF
alpha increase that occurred in the placebo group but not
in the IFN treated patients. Although IFN gamma has been
considered as a pro-inflammatory molecule, more and
more evidences of anti-inflammatory actions exist, which
supposes a dual effect [52].
Conclusion
The results obtained may justify the rationality to use IFN
gamma as adjuvant to antimycobacterial drugs in patients
with pulmonary atypical Mycobacteriosis, mainly in MAC
infection, which is the most frequent. Their combination
could reduce treatment duration, toxicities and possible
relapses. In some cases it could prevent recessional sur-
gery. Further, more extensive, controlled clinical trials are
encouraged to confirm this assessment.
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